<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pacific Breast Pathology &#187; chemotherapy</title>
	<atom:link href="http://www.pacificbreastpathology.com/blog/tag/chemotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pacificbreastpathology.com/blog</link>
	<description>Pacific Breast Pathology weblog</description>
	<lastBuildDate>Fri, 16 Dec 2011 21:08:18 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Understanding Pathology Results</title>
		<link>http://www.pacificbreastpathology.com/blog/ask_the_pathologist/understanding-pathology-results/</link>
		<comments>http://www.pacificbreastpathology.com/blog/ask_the_pathologist/understanding-pathology-results/#comments</comments>
		<pubDate>Tue, 11 Oct 2011 15:25:02 +0000</pubDate>
		<dc:creator>drlawton</dc:creator>
				<category><![CDATA[Ask the Pathologist]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[breast cancer stage]]></category>
		<category><![CDATA[carcinoma in situ]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[core biopsy]]></category>
		<category><![CDATA[estrogen receptor]]></category>
		<category><![CDATA[HER2]]></category>
		<category><![CDATA[invasive carcinoma]]></category>
		<category><![CDATA[pathologist]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.breastpathologyconsults.com/blog/?p=943</guid>
		<description><![CDATA[Question:  Can you help me understand this report?
Breast Right, biospy:
Infiltrating ductal carcinoma
SBR/Nottingham grade 2/3
Tubular score 2.
Nuclear score 2.
Mitotic score 2 (focal).
No evidence of angiolymphatic invasion
Cancerization og lobules
Ductal carcinoma in situ
Solid, papillary and cribriform patterns
Nuclear grade 2-3
Comedonecrosis present
Microcalcifications associated with in situ malignancy
Immunostains -
Estrogen receptor &#8211; diffuse strong positivity in 97% of tumor cell nuclei
Progesterone receptor [...]]]></description>
		<wfw:commentRss>http://www.pacificbreastpathology.com/blog/ask_the_pathologist/understanding-pathology-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Research on Using Immunohistochemistry to Predict Response to Neoadjuvant Chemotherapy</title>
		<link>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/new-research-on-using-immunohistochemistry-to-predict-response-to-neoadjuvant-chemotherapy/</link>
		<comments>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/new-research-on-using-immunohistochemistry-to-predict-response-to-neoadjuvant-chemotherapy/#comments</comments>
		<pubDate>Mon, 08 Feb 2010 23:37:22 +0000</pubDate>
		<dc:creator>drlawton</dc:creator>
				<category><![CDATA[PBP Blog]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[HER2]]></category>
		<category><![CDATA[immunohistochemistry]]></category>

		<guid isPermaLink="false">http://www.breastpathologyconsults.com/blog/?p=586</guid>
		<description><![CDATA[In the online &#8220;early view&#8221; section of the journal Cancer there is a new research article proposing that using three currently-used immunohistochemical breast markers in a group of patients who received neoadjuvant chemotherapy, doctors can sub-type cancers similar to those described by molecular profiling.  They also suggest these sub-types are associated with different responses to treatment and overall survival. [...]]]></description>
		<wfw:commentRss>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/new-research-on-using-immunohistochemistry-to-predict-response-to-neoadjuvant-chemotherapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Breast Cancer Treatment Options</title>
		<link>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/breast-cancer-treatment-options/</link>
		<comments>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/breast-cancer-treatment-options/#comments</comments>
		<pubDate>Wed, 24 Sep 2008 20:43:08 +0000</pubDate>
		<dc:creator>drlawton</dc:creator>
				<category><![CDATA[PBP Blog]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[carcinoma in situ]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[HER2]]></category>
		<category><![CDATA[invasive carcinoma]]></category>
		<category><![CDATA[pathologist]]></category>
		<category><![CDATA[second opinion]]></category>
		<category><![CDATA[stage]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.breastpathologyconsults.com/blog/?p=187</guid>
		<description><![CDATA[Many patients ask how they know if they are getting the appropriate treatment for their breast cancer. No two patients are alike and therefore treatment decisions are based upon your unique situation and the type of cancer you have. This is one reason why it is important to get a second opinion on your pathology [...]]]></description>
		<wfw:commentRss>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/breast-cancer-treatment-options/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HER2 and Neoadjuvant Chemotherapy</title>
		<link>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/her2-and-neoadjuvant-chemotherapy/</link>
		<comments>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/her2-and-neoadjuvant-chemotherapy/#comments</comments>
		<pubDate>Fri, 19 Sep 2008 20:03:46 +0000</pubDate>
		<dc:creator>drlawton</dc:creator>
				<category><![CDATA[PBP Blog]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[HER2]]></category>
		<category><![CDATA[invasive carcinoma]]></category>

		<guid isPermaLink="false">http://www.breastpathologyconsults.com/blog/?p=130</guid>
		<description><![CDATA[A recent study from MD Anderson Cancer Center looked at a group of women with breast cancers that tested positive for HER2 over-expression who received neoadjuvant chemotherapy.  Of the women who still had residual invasive cancer in their breast following their surgery, approximately 30% of them had cancers that were now HER2 negative.
We performed a [...]]]></description>
		<wfw:commentRss>http://www.pacificbreastpathology.com/blog/dr_lawtons_blog/her2-and-neoadjuvant-chemotherapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

